NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
This screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival.
The purpose of this study is to utilize clinical and biological data to screen for eligibility to phase 2 pathway-targeting specific subprotocols of pathway-targeting agents in pediatric patients with advanced solid tumors, non-Hodgkin lymphomas, and histiocytic disorders; to determine the proportion of pediatric patients whose advanced tumors have pathway alterations that can be targeted by select anti-cancer drugs; and to determine the objective response rates (ORR; complete response + partial response) in pediatric patients with advanced solid tumors, non-Hodgkin lymphomas, and histiocytic disorders harboring a priori specified genomic alterations treated with pathway-targeting agents.
Participant will not be paid for their participation.
- IRB Number: 1709401165 (PHO-PRADHAN-COG-APEC1621)
- Research Study Identifier: TX8293
- Principal Investigator: Batra Sandeep, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required